Dr. Reddy’s Laboratories is looking to scale its presence in semaglutide as the market opened up following patent expiry, with plans to expand both in India and globally. M V Ramana, CEO – Branded Markets (India and Emerging Markets), says the company is focusing on improving access in a market where adoption remains low despite a large diabetes burden, while building capabilities across development and manufacturing. He adds that Dr. Reddy’s is developing a broader portfolio across metabolic therapies, including diabetes and obesity, and is preparing for launches in multiple markets as patents expire globally. The company is also targeting a position among the top players in the segment, with emphasis on physician confidence, patient adherence and supply continuity.
Business Today, Dr Reddy's, M V Ramana, Semaglutide, Diabetes Care, Obesity Treatment#Reddys #Plans #Global #Semaglutide #Rollout #Patents #Expire1774263822
business today
Diabetes Care
Dr Reddy's
Expire
Global
M V Ramana
Obesity Treatment
patents
Plans
Reddys
Rollout
Semaglutide
Recent Post
Gallery
Featured Videos
